Eicosanoid Control Over Antigen Presenting Cells in Asthma

Nincy Debeuf1,2 and Bart N. Lambrecht1,2,3*

1 Laboratory of Immunoregulation, VIB-UGent Center for Inflammation Research, Ghent, Belgium, 2 Department of Internal Medicine, Ghent University, Ghent, Belgium, 3 Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, Netherlands

Asthma is a common lung disease affecting 300 million people worldwide. Allergic asthma is recognized as a prototypical Th2 disorder, orchestrated by an aberrant adaptive CD4+ T helper (Th2/Th17) cell immune response against airborne allergens, that leads to eosinophilic inflammation, reversible bronchoconstriction, and mucus overproduction. Other forms of asthma are controlled by an eosinophil-rich innate ILC2 response driven by epithelial damage, whereas in some patients with more neutrophilia, the disease is driven by Th17 cells. Dendritic cells (DCs) and macrophages are crucial regulators of type 2 immunity in asthma. Numerous lipid mediators including the eicosanoids prostaglandins and leukotrienes influence key functions of these cells, leading to either pro- or anti-inflammatory effects on disease outcome. In this review, we will discuss how eicosanoids affect the functions of DCs and macrophages in the asthmatic lung and how this leads to aberrant T cell differentiation that causes disease.

Keywords: eicosanoids, prostaglandins, leukotrienes, asthma, dendritic cells, macrophages

PRIMER ON EICOSANOIDS, PROSTAGLANDINS AND LEUKOTRIENES

Eicosanoids are an important class of biologically active molecules, comprising prostanoids, leukotrienes (LTs) and lipoxins that have important pro- and anti-inflammatory effects in asthma. Under a variety of non-specific activation stimuli, such as pro-inflammatory mediators and other stress, the precursor molecule arachidonic acid (AA) is released from membrane phospholipids by cytosolic phospholipase A2. AA can be enzymatically converted either to prostanoids [prostaglandin (PG) and thromboxane] by COX enzymes or to LT and lipoxins by lipoxygenases (LOXs) (Figure 1).

Prostanoids The COX isozymes (constitutive COX-1 and inducible COX-2) catalyze the formation of PGG2, which is then reduced to the intermediate PGH2 through peroxidase activity. Various cell-specific PG synthases convert PGH2 to biologically active products, such as PGE2, PGJ2, PGD2 and PGF2a and thromboxane (TXA2) (1). The differential expression and the distribution of these enzymes within cells present at sites of inflammation will determine the profile of prostanoid production. For instance, mast cells predominantly generate PGD2 through their expression of hematopoietic PGD synthase (hPGDS). Through microsomal PGE2 synthase (mPGES-1), PGE2 is produced by virtually all lung cell types, but the most abundant sources are epithelial cells, fibroblasts, and macrophages (1). Prostanoids act in both paracrine and autocrine fashion through G protein-coupled receptors (GPCRs) on the surface of target cells. Interestingly, the distribution of prostanoid receptors on immune cells differs from the distribution of prostanoid-specific synthases. Prostanoid synthases are mainly expressed on innate immune...
cells, whereas prostanoid receptors are expressed on both innate and adaptive immune system leukocytes (2). So, during inflammation, activated innate immune cells will produce prostanooids that act on lymphocytes in a paracrine manner and also modulate their own function in an autocrine way (3).

Leukotrienes are generated by LOX enzymes. The different LOX enzymes are named based on their positional specificity of AA oxygenation. For instance, 12-LOX oxygenates AA at carbon 12, resulting in 12-hydro(peroxy)eicosatetraenoic acid [12-H(P)ETE] (4). Since the human leukocyte-type 12-LOX is very similar to reticulocyte-type 15-LOX, these enzymes are often referred to in the literature as 12/15-LOXs (5). Furthermore, mice do not express 15-LOX and only express the leukocyte-derived 12-LOX. Because murine 12-LOX is also able to generate 15-H(P)ETE, the enzyme is often designated as 12/15 LOX as well (6).

5-lipoxygenase (5-LOX) generates the leukotriene LTA₄, an unstable intermediate, which is converted to the chemoattractant LTD₄ or to nonchemotactic LTC₄ by the cytosolic LTA₄ hydrolase enzyme or leukotriene C₄ synthase (LTC₄S) respectively. LTC₄ is exported to the extracellular space and is further converted to the unstable LTD₄ and subsequently to the stable end-metabolite LTE₄ (7). LTC₄, LTD₄ and LTE₄ belong to the so-called cysteinyl leukotrienes, due to the presence of the amino acid cysteine in their structure. There are at least three different cysteinyl leukotriene receptors (CysLTR1, CysLTR2, and CysLTR3). LTE₄ preferably binds CysLTR3 (8), whereas LTC₄ binds CysLTR2 and LTD₄ binds both CysLTR1 and CysLTR2 (9, 10).

Leukotrienes are predominantly produced by leukocytes, hence their name. However, the specific profile of LTs produced depends on the cell type. Neutrophils produce exclusively LTD₄, whereas mast cells, basophils and eosinophils mainly produce cysteine LTs. Macrophages and DCs synthesize both LTD₄ and cysteine LTs (11).

Lipoxins (LXA₄ and LXB₄) are short-lived eicosanoids that are derived from arachidonic acid through sequential activity of 5-LOX and 12/15-LOX. 15-LOX is a key enzyme for lipoxin generation in the human lung and is expressed by many cells during inflammation, including macrophages, eosinophils and bronchial epithelial cells (12–14).

**EICOSANOIDS HAVE MULTIPLE EFFECTS IN ALLERGIC ASTHMA**

Asthma is a chronic inflammatory disease of the airways, characterized by reversible bronchoconstriction, airway remodeling and mucus production. Most childhood-onset asthma and half of the adult-onset asthma cases are allergic, identified by a positive skin prick test or the detection of serum IgE antibodies against common antigens, such as plant and tree pollen, animal dander, house dust mites (HDM) and fungal spores. Virtually all cell types relevant to Th2 pathology such as Th2 cells, ILC2s, mast cells, basophils, epithelial cells, smooth muscle cells and fibroblasts generate LT and/or PG mediators, and/or express receptors for those eicosanoids (Figure 2). Among prostanoids, PGD₂ released from mast cells, has long been implicated in allergic diseases (15). PGD₂ is known to have chemotactic effects on eosinophils, basophils, Th2 lymphocytes and ILC2s acting via the DP2/CRTH2 receptor (16, 17) and in this way contributes to airway hyperresponsiveness, IgE and cytokine secretion (18–20). PGD₂ levels and the number of CRTH2+ cells are increased in bronchoalveolar lavage (BAL) fluids from severe asthmatics compared to those with milder disease (21). Several CRTH2 antagonists have shown encouraging results in clinical trials for asthma, further supporting for the role of PGD₂ in allergic diseases and its potential as a therapeutic target (22).

Although cyclooxygenase and its products, PGs, have been traditionally linked to all four cardinal signs of inflammation (redness, swelling, heat, pain), prostanoids may also have an inhibitory role on inflammatory cells. This discrepancy can be explained by the fact that typical inflammation hallmarks are the result of actions on microvasculature, hypothalamus and nerves, rather than on immune cells. In mouse models of asthma, PGs have pleiotropic effects. PGI₂ can abolish asthma development by inhibition of DC activation and Th2 cell migration (23–25), whereas PGE₂ can reduce mast cell secretory responses (26–29) and chemotaxis of eosinophils (30). Furthermore, both PGI₂ and PGE₂ can inhibit cytokine release of both Th1 and Th2 CD4+ T cells and macrophages (31, 32). Treg differentiation and function is also promoted by PGE₂ (33, 34).

Prostanoids are also able to inhibit airway remodeling and mucus secretion in asthma models in vivo (35–37). It has been shown that PGE₂ induces fibroblast apoptosis (38), abolishes myofibroblast differentiation (39) and inhibits proliferation of airway smooth muscle cells (40).

In asthma patients, inhalation of exogenous PGE₂ or its analogs results in bronchodilatation and protection against early- and late-phase bronchoconstriction induced by various asthma triggers (41–43). Despite the benefits of inhaled PGE₂, it has also been reported that prostanoids can induce irritancy of the upper airway resulting in a reflex cough. However, this can be overcome by treatment with a receptor-selective agonist, as cough is exclusively mediated via the EP3 receptor (44).

In contrary to the bronchodilatory properties of the prostaglandin PGE₂, CysLTs are an important cause of allergen-induced bronchoconstriction (45). Indeed, treatment with Cysteinyl LT receptor 1 antagonists (LTRAs) attenuates allergen-induced increases in airway hyperresponsiveness (46, 47). Furthermore LTRAs partially attenuate allergen-induced airway eosinophilia (47, 48), demonstrating a more extensive role for LTs in asthma. Indeed, CysLTs that are also released from mast cells, particularly LTE₄, can cause eosinophil chemotaxis in allergic asthmatics (49). Interestingly, CysLT levels are also increased in BAL fluid (50) and in urine after allergen challenge (51). Currently, LTRAs (such as montelukast) are clinically available. Although these drugs are superior to placebo at decreasing asthmatic symptoms and exacerbations, LTRAs are not recommended as first line therapy for asthma. The reason for this is that they are generally inferior to
Debeuf and Lambrecht Eicosanoid Control Over APCs in Asthma

**FIGURE 1** | Schematic overview of eicosanoid biosynthesis. Arachidonic acid that is released from membrane phospholipids by cytosolic phospholipase A2 (PLA2), can be enzymatically converted either to prostaglandins (PG) and thromboxane (TXA2) by COX enzymes or to LT and lipoxins (LXA4) by lipooxygenases (LOXs).

Inhaled corticosteroids in anti-inflammatory and clinical effects\(^1\). Furthermore, about one third of the asthma patients does not respond to LTRAs (52).

Another type of leukotriene, LTB4, through its actions on the BLT1 receptor, is an activator and chemoattractant for different cell types such as T cells (53, 54) and DCs (55). OVA-induced allergic inflammation was completely abolished in BLT1 deficient mice, demonstrating the importance of BLT1 and its ligand LTB4 in the development of allergic airway inflammation (56).

Lipoxins have a pro-resolution role in allergic airway inflammation. In severe asthmatics, blood LXA4 levels and leukocyte LXA4 generation are reduced compared to those with milder disease (57–59). In a mouse model of asthma, administration of a stable analog of LXA4 resulted in a diminished airway hyperresponsiveness and pulmonary inflammation (60, 61). Similar results were obtained with resolvins and protectins. Those mediators are also generated by LOX enzymes, but are derived from omega-3 polyunsaturated fatty acids instead of the substrate arachidonic acid (62–64).

Finally, absence of all eicosanoids impairs the induction of a Th2 response and reduces airway inflammation. This has been shown with mice lacking group V secretory phospholipase A2 (sPLA2), which is the enzyme that releases AA from membrane lipids and catalyzes the first step of eicosanoid generation. Deletion of sPLA2 attenuates cell migration and airway hyperresponsiveness, whereas sPLA2 overexpression is associated with severe asthma (65–68). An impaired antigen capture activity and maturation of DCs is responsible for the inhibition of asthma development in sPLA2\(^{-/-}\) mice (69).

**CURRENT INSIGHTS IN ALLERGIC ASTHMA PATHOGENESIS: A CENTRAL ROLE FOR DENDRITIC CELLS**

In allergic asthma, airway DCs take up allergens across the epithelial barrier and subsequently activate Th2 immunity in the draining lymph nodes, leading to IgE responses and to Th2 effector cells that control eosinophilic airway inflammation.

---

\(^1\)National Institutes of Health; National Heart, Lung, and Blood. National Asthma Education and Prevention Program Institute, Expert panel report 3: guidelines for the diagnosis and management of asthma. No. 07–4051 Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm 2007.
Eicosanoids have multiple effects in allergic asthma. In response to allergens and/or instructive cytokines by epithelial cells and innate immune cells, dendritic cells activate Th2 immunity in the draining lymph nodes, leading to IgE responses and to Th2 effector cells that control eosinophilic airway inflammation, goblet cell metaplasia and bronchial hyperreactivity upon return to the lung. Virtually all cell types relevant to Th2 pathology such as Th2 cells, ILC2s, mast cells, basophils and epithelial cells, generate leukotriene/prostaglandin mediators, and/or express receptors for those eicosanoids. The figure represents a schematic overview of eicosanoid functions described in this review.

FIGURE 2 | Eicosanoids have multiple effects in allergic asthma. In response to allergens and/or instructive cytokines by epithelial cells and innate immune cells, dendritic cells activate Th2 immunity in the draining lymph nodes, leading to IgE responses and to Th2 effector cells that control eosinophilic airway inflammation, goblet cell metaplasia and bronchial hyperreactivity upon return to the lung. Virtually all cell types relevant to Th2 pathology such as Th2 cells, ILC2s, mast cells, basophils and epithelial cells, generate leukotriene/prostaglandin mediators, and/or express receptors for those eicosanoids. The figure represents a schematic overview of eicosanoid functions described in this review.
T cells fail to function properly in the absence of pDCs (91, 93, 94).

Although DCs express PRRs and can sense the environment directly, the epithelium has been shown to be equally important in activating DCs in response to allergens (95). As this is beyond the scope of this review, we refer to Hammad and Lambrecht for a recent review describing the role of epithelial cytokines in the activation of DCs during allergic inflammation (96). In brief, DCs get activated by epithelial cytokines like IL-33, GM-CSF, IL-1a, IL-25, and thymic stromal lymphopoietin (TSLP). The same cytokines also activate ILC2s, basophils and Th2 effector cells to become cytokine producing cells and contribute to the initiation of a Th2 response (70, 71, 97). The release of epithelial cytokines is elicited by environmental stimuli of asthma, such as HDM, viruses, diesel particles and cigarette smoke. On the other hand, protective environments, such as farm dust or lipopolysaccharide exposure, have the potential to suppress this cytokine release and DC activation (98).

**EICOSANOIDS AFFECT THE MIGRATION OF DENDRITIC CELLS**

The control of DC migration is pivotal for the initiation of cellular immune responses. Upon activation by inflammatory stimuli, DCs upregulate the chemokine receptor CCR7 and home to lymphoid organs, where the CCR7 ligands CCL19 and CCL21 are expressed. This migratory capacity of DCs requires environmental instruction by PGE2. PGE2 has no effect on the expression of CCR7 on DCs, but couples CCR7 expression to signal transduction pathways such as activation of cAMP-dependent protein kinase A (PKA) and Rho Kinase (99). These signals allow the DCs to start migration, among other by inducing a rapid disassembly of podosomes (100). Surprisingly, PGE2 was only required at early time points of maturation to enable DC chemotaxis, whereas PGD2 addition has no effect during terminal maturation. Mouse DCs exclusively rely on EP4 receptor triggering for migration, whereas human MCs require a signal mediated by EP2 or EP4 either alone or in combination (101, 102).

In contrary to PGE2, PGD2, and PGJ2 inhibit the maturation and migration of DCs. In the skin, Angeli and colleagues showed that parasite-derived PGD2 inhibits the migration of epidermal Langerhans cells to the skin draining lymph nodes and affects the subsequent cutaneous inflammatory reaction (103). Similarly, intratracheal instillation of FITC-OVA together with PGD2 inhibits the migration of FITC+ lung DC to draining LNs. Activation of the DP1 receptor was responsible for this inhibition (104). DP1 activation also lowers the expression of costimulatory molecules on DCs and enhances the induction of Foxp3+ Treg cells, resulting in an abolished asthma phenotype (34). Inhalation of iloprost, a stable PGD2 analog, also suppressed the cardinal features of asthma by interfering with the function of lung myeloid DC. Furthermore, iloprost-treated DCs no longer induced Th2 differentiation from naive T cells or boosted effector cytokine production in primed Th2 cells, showing that the effect of iloprost was DC intrinsic (23).

CysLT enhance the migration of DCs. Indeed, DCs lacking the LTC4 transporter multidrug resistance-associated protein 1 (MRP1) failed to migrate to the lymph nodes, whereas exogenous LTC4 or LTD4 could restore this migration. However, these CysLTs only promoted optimal chemotaxis to the chemokine CCL19, but not to other related chemokines (105). On the other hand, lipoxins were able to inhibit DC migration (106).

**EICOSANOID SIGNALING IN DCs MODULATES INSTRUCTION OF T CELL DIFFERENTIATION**

Upon DC-T cell encounter, DCs produce cytokines that drive Th differentiation. The secretion pattern of these cytokines, and thus the Th1/Th2 balance can be modulated by a variety of biologically active mediators synthesized by innate and adaptive immune cells. Eicosanoids such as PGE2 exert a great impact on this regulation. For instance, the ratio of PGE2 and IL-12, both produced by APCs, may control the balance between Th1 and Th2 immunity (107). Basically, it has been shown that PGE2 is a potent inhibitor of IL-12 production (108) and in this way favors a Th2 response (109–112). PGE2 also inhibits the secretion of TNF-α from murine DCs (113, 114). The inhibitory role of PGE2 on DC cytokine secretion can also be indirect by inducing IL-10 secretion (108, 113, 115). Due to its inhibitory effect on IL-12, PGE2 also indirectly inhibits IFN-γ secretion by T cells and NK cells (110, 116).

Beside the Th2 inducing role for PGE2, it has also been reported that PGE2-treated DCs can induce Th1 and Th17 responses. Adding PGE2 together with TNF-α to human BMDCs stimulates IL-12 production by DCs, favoring a Th1 response (117–121). PGE2 also stimulates IL-23 production by cultured BMDCs and promotes in this way Th17 differentiation (122, 123).

Prostanoids can also directly modify production of Th cytokines from polarized T cells. PGE2 can favor Th2 immunity by inhibiting IL-2 and IFN-γ production by Th1 cells, but not the production of IL-4 by Th2 cells (124, 125). However, in a mouse model of asthma, PGE2 has also been shown to inhibit Th2 responses via direct effects on the EP2 receptor on T cells (126). Furthermore, PGE2 regulates Th17 cell differentiation and cytokine secretion directly through EP2/EP4 receptor signaling on T cells (127). Via DP1, PGD2 can block the expression of the Th1 cytokine IFN-γ. Furthermore, Th2 cytokine secretion is increased through CRTH2 signaling (128). On the other hand, PGJ2 can directly inhibit production of Th2 cytokines from Th2 polarized mouse splenic CD4+ cells (32, 129), thus directly exhibiting lower levels of Th2 response.

Less is known about the role of leukotrienes on T cell polarization. Machida et al. reported that in vitro treatment with LTRAs modifies the cytokine profile of DCs (130). By in vivo administration of LTRAs, Okunishi and colleagues showed that LTs promote DC antigen presentation and both Th1 and Th2 polarizing cytokine secretion (131).

Furthermore, using LTC4−/− and CysLTR1−/− mice, it has been demonstrated that leukotrienes are crucial for the initiation
of a Th2 response upon HDM-dependent Dectin-2 activation on DCs (132). Through CysLTR1, LTD₄ can induce IL-4 secretion by ILC2s, contributing to Th2 polarization as well (133). CysLTR1 can also be up-regulated in activated CD4⁺ T cells themselves and can mediate their chemotaxis to LTD₄, but whether cysLTs exert a direct effect on cytokine production by CD4⁺ T cells remains unclear (134). This is different from the leukotriene LTB₄, which increases cytokine production by T cells (135), but does not affect antigen presentation and cytokine production by DCs (55). Strikingly, mice deficient in CysLTR2 or adoptive transfer of DCs lacking CysLTR2 developed markedly enhanced Th2 immunity to HDM. In fact, CysLTR2 negatively regulates cell surface expression and receptor signaling of DCs (136). Thus, the biologic activity of CysLTs can be tightly regulated by competition between the different expressed CysLT receptors.

12/15-LOX enzymes, required for lipoxin synthesis, are also involved in the modulation of Th2 cytokine secretion. In response to IL-13, DCs secrete the lectin Ym1/2 that might interact with 12/15-LOX in or at the surface of T cells. 12/15-LOX generates 12-HETE that has been shown to reduce Th2 cytokine secretion both in vivo and in vitro. Furthermore, 12-HETE attenuated airway eosinophilia in an OVA-induced allergic asthma model. However, DC-secreted Ym1/2 was able to decrease the expression of 12-HETE, suggesting that the asthma-promoting effects of Ym1/2 might be explained by inhibiting 12/15-LOX on T cells (137).

EICOSANOIDS ALSO AFFECT ANTIGEN-PRESENTING B CELLS AND ILC2S

The most described function of B cells is their production of antigen-specific immunoglobulins. However, in addition to antibody production, activated B cells also play a role as accessory antigen-presenting cells. Although they are not as potent as DCs in priming naïve T cells, they are abundantly present in T-cell inducive sites, express costimulatory molecules and produce cytokines that activate DCs and naïve T cells (138–141). Their antigen-presenting and Th2-promoting effects have also been demonstrated in murine asthma models, with a particular role during secondary challenge and when the antigen dose is limiting (142).

Numerous studies have shown that eicosanoids are required for both the development and function of lymphocytes (143–147). PGE₂ is necessary for IgE production both in vitro and in vivo, by affecting IgE class switching (145, 148–151). Furthermore, PGE₂ has been demonstrated to regulate B cell proliferation (152). Interestingly, PGE₂ is also able to lower MHCII expression on B cells (148), but whether this affects antigen presentation is still unclear. Leukotrienes, in particular LTD₄, can enhance immunoglobulin production as well (153). In contrast, lipoxins have the opposite effect as 12/15-LOX deficiency protects mice from allergic airway inflammation by increasing secretory IgA levels (147).

Strikingly, ILC2s have also been shown to present antigen (154, 155). In response to the parasitic worm *Nippostrongylus brasiliensis*, MHC class II expression on ILC2s was required for the induction of an efficient Th2 response. ILC2s express the costimulatory receptors CD80 and CD86, acquire and process antigen and interact with antigen-specific T cells. During this interaction, T cell-derived IL-2 promotes ILC2 proliferation and IL-13 production (153) and this can be affected by eicosanoids. PGE₂ and CysLTs stimulate Th2 cytokine production from ILC2s (133, 156, 157), whereas other lipid mediators have suppressive roles on ILC2 function. The pro-resolving mediator LXA₄ could inhibit ILC2 activation (156) and both PGE₂ and PGD₂ were able to attenuate ILC2 proliferation, Th2 cytokine generation and resulting type 2 immune response (158, 159).

EICOSANOIDS MODULATE THE TOLEROGIC ROLE OF MACROPHAGES IN THE ALLERGIC LUNG

Lung macrophages can be divided into alveolar macrophages (AMs) and interstitial macrophages (IMs). AMs are most abundantly present and are situated in the alveolar lumen, while IMs are located inside the lung interstitium. During inflammation, a third population emerges, as monocyte-derived macrophages infiltrate the alveolar and interstitial areas. Macrophages express different eicosanoid receptors, such as the receptors for PGE₂ and PGD₂. Furthermore, macrophages produce both prostaglandins and leukotrienes themselves, allowing autocrine regulation (160).

AMs are sessile, long-lived, and self-renewing cells that derive from fetal monocytes under the influence of GM-CSF (161–164). Several studies have clearly demonstrated that resident AMs induce a tolerogenic response to inhaled antigens (164–171). Use of liposomal clodronate to deplete resident AMs in an OVA or HDM-induced asthma model, favored a Th2 response and subsequently resulted in increased BAL eosinophilia and inflammatory cytokine levels (167, 168). One possible mechanism for this inhibitory role of macrophages is the secretion of SOCS1 and SOCS3 in exosomes and microparticles. The uptake of these particles by alveolar epithelial cells inhibits their activation in a JAK/STAT-dependent way (169). PGE₂ is a major epithelium-derived factor mediating SOCS secretion (170) and in this way inhibiting the development of allergic lung inflammation (171). Indeed, in a HDM-dependent asthma model, adoptive transfer of PGE₂-treated macrophages led to a reduction in eosinophilia in the allergic lung (171).

Pulmonary inflammation was also reduced if macrophages lacked group V sPLA₂, which is the enzyme releasing AA from membrane lipids and is required for both PG and LT synthesis (172). Those macrophages generated less PGE₂, resulting in a diminished transglutaminase activity of M2 macrophages (173). Furthermore, by activating the EP4 receptor on macrophages, PGE₂ inhibits TNF-α and IL-12 cytokine secretion (31). The ability of lung macrophages to prevent Th2 induction in response to inhaled allergens has also been demonstrated in rats. The replacement of AM of sensitized animals by AM from naive animals completely abolished Th2 polarization by inhibition of DC allergen capture and migration to the lymph nodes (174).
Although PGE$_2$ suppresses type 2 inflammation in most settings, a recent study demonstrated that PGE$_2$ also has pro-inflammatory effects in murine macrophages. Mice lacking microsomal PGE synthase 1 (mPGE1) had an attenuated asthma phenotype compared to wild-type controls in response to repetitive inhalation challenges with an extract from the allergic mold Alternaria alternata, which could be explained by a diminished IL-33 production by murine macrophages (175).

The pro-inflammatory prostanooid PGD$_2$ binds both the DP1 and DP2 receptor on lung macrophages. DP signaling enhances migration and TNF-α secretion of both alveolar and interstitial macrophages. Furthermore, PGD$_2$ also induces KC secretion from macrophages, resulting in neutrophil recruitment in the lung and this neutrophilia could be abolished by macropage depletion (176). Interestingly, PGD$_2$ synthesis by macrophages is also involved in the enhancement of airway inflammation by virus infections. Respiratory infections with RNA viruses, such as rhinovirus or respiratory syncytial virus (RSV), are associated with asthmatic exacerbations (177). To study the mechanism behind this association, Shiraiishi and colleagues administered polyclonal antibody, a synthetic dsRNA, intratracheally in OVA-sensitized rats. Those rats developed an exacerbated asthma phenotype and had elevated PGD$_2$ synthesis in the lung, particularly in AMs. CRTH2-deficient animals did not exhibit a dsRNA-induced increase in eosinophil accumulation, demonstrating the necessary role for PGD$_2$ in dsRNA-induced enhancement of airway inflammation (178).

RSV infection of mice deficient in 5-LOX, an enzyme required for lipoxin synthesis, resulted in stronger lung pathology compared to wildtype mice, due to a lack of alternatively activated macrophages (179, 180). Treatment with LXA$_4$ partially restored this, supporting a pro-resolution role for lipoxins in viral respiratory tract infections (180).

Just as described for DCs, AMs produce leukotrienes in response to HDM-driven Dectin-2 activation. Both an inhibitor of LT production and Dectin-2 blockade could prevent the development of bronchial hyperreactivity and airway inflammation, demonstrating the required role for Dectin-2 dependent leukotriene production in the initiation of allergic airway inflammation (181).

**REFERENCES**

1. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* (2001) 294:1871–5. doi: 10.1126/science.294.5548.1871
2. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. *J Clin Invest.* (2001) 108:15–23. doi: 10.1172/JCI200113416
3. Harizi H, Gualde N. The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. *Tissue Antigens* (2005) 65:507–14. doi: 10.1111/j.1399-0039.2005.00394.x
4. Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. *J Biol Chem.* (2013) 288:10967–72. doi: 10.1074/jbc.C113.453704
5. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK, Lin SH, Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. *Mol Pharmacol.* (2000) 58:1601–8. doi: 10.1124/mol.58.6.1601
6. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. *Nature* (1999) 399:789–93. doi: 10.1038/21658
7. Samuchiwal SK, Boyce JA. Role of lipid mediators and control of lymphocyte responses in type 2 immunopathology. *J Allergy Clin Immunol.* (2018) 141:1182–90. doi: 10.1016/j.jaci.2018.02.006
8. Peters-Golden M, Henderson WR Jr. Leukotrienes. *N Engl J Med.* (2007) 357:1841–54. doi: 10.1056/NEJMra071371
9. Hunter JA, Finkbeiner WE, Nadel JA, Goetzl EJ, Holtzman MJ. Predominant generation of 15-lipoxygenase metabolites of arachidonic acid by epithelial cells from human trachea. *Proc Natl Acad Sci USA.* (1985) 82:4633–7. doi: 10.1073/pnas.82.14.4633

**AUTHOR CONTRIBUTIONS**

ND wrote the first draft of the manuscript. BL edited the manuscript. Both authors contributed to manuscript revision, read and approved the submitted version.

**FUNDING**

ND is supported by a Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO) grant (11Y8417N). BL is supported by an European Research Council (ERC)-Consolidator grant (EU789384) and Excellence of Science (EOS) research grant (project 30565447).
Debeuf and Lambrecht Eicosanoid Control Over APCs in Asthma

13. Levy BD, Romano M, Chapman HA, Reilly JJ, Drazen J, Serhan CN. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest. (1993) 92:1572–9. doi: 10.1172/JCI16738

14. Serhan CN, Hirsch U, Palmblad J, Samuelsson B. Formation of lipoxin A by granulocytes from eosinophilic donors. FEBS Lett. (1987) 217:242–6. doi: 10.1016/0014-5793(87)80671-3

15. Hardy CC, Robinson C, Tattersfield AE, Holgate ST. The bronchouchronicosteroid effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med. (1984) 311:209–13. doi: 10.1056/NEJM198407263111401

16. Hiri H, Tanaka K, Yachie O, Ogawa K, Kenmotsu K, Takamori Y, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. (2001) 193:255–61. doi: 10.1084/jem.193.2.255

17. Nagata K, Hira H, Tanaka K, Ogawa K, Asa T, Sugumura K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. (1999) 459:195–9. doi: 10.1016/S0014-5793(99)01251-X

18. Pettipher R, Whittaker M. Update on the development of prostanoid receptor antagonists. Biochem Pharmacol. (2003) 65:2019–29. doi: 10.1016/S0006-2952(03)00688-6

19. Xue L, Salimi M, Panse J, Mjosberg JM, McKenzie ANJ, Spits H, et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemokine receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol. (2014) 133:1184–94. doi: 10.1016/j.jaci.2013.10.056

20. Chang JE, Doherty TA, Baum R, Broide D. Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis. J Allergy Clin Immunol. (2014) 133:899–901.e3. doi: 10.1016/j.jaci.2013.09.020

21. Fajt ML, Gelhaus SL, Freeman B, Uvalle CE, Trudeau JB, Holguin F, et al. Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol. (2013) 131:1504–12. doi: 10.1016/j.jaci.2013.01.035

22. George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. (2016) 7:34–51. doi: 10.1177/204062231669251

23. Izdko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, et al. Inhaled iloprost suppresses the cardiolipin features of asthma via inhibition of airway dendritic cell function. J Clin Invest. (2007) 117:864–72. doi: 10.1172/JCI28949

24. Nago K, Tanaka H, Komai M, Masuda T, Narumiya S, Nagai H. Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice. Am J Respir Cell Mol Biol. (2003) 29:314–20. doi: 10.1165/rcmb.2003-0035OC

25. Jaffar Z, Ferrini ME, Buford MC, FitzGerald GA, Roberts K. Prostaglandin E2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ TH2 cells into the airways in a mouse model of asthma. J Immunol. (2007) 179:6193–203. doi: 10.4049/jimmunol.179.9.619

26. Herrerias A, Torres R, Serra M, Marco A, Roca-Ferrer J, Picado C, et al. Subcutaneous prostaglandin E2 restrains airway mast cell activity in vivo and reduces lung eosinophilia and Th(2) cytokine overproduction in house dust mite-sensitive mice. Int Arch Allergy Immunol. (2009) 149:322–32. doi: 10.1159/000205578

27. Torres R, Pérez M, Marco A, Picado C, de Mora F. A Cyclooxygenase-2 selective inhibitor worsens respiratory function and enhances mast cell activity in ovalbumin-sensitized mice. Arch Bronconeumol. (English Edition) (2009) 45:162–7. doi: 10.1016/j.arbres.2008.04.007

28. Torres R, Herrerias A, Serra-Pagés M, Marco A, Plaza J, Costa-Farré C, et al. Locally administered prostaglandin E2 prevents aerosol-induced airway sensitization in mice through immunomodulatory mechanisms. Pharmacol Res. (2013) 70:50–9. doi: 10.1016/j.phrs.2012.12.008

29. Kay LJ, Yeo WW, Peachell PT. Prostaglandin E2activates EP receptors to inhibit human lung mast cell degranulation. Br J Pharmacol. (2006) 147:707–13. doi: 10.1039/b607066a

30. Sturm EM, Scharl P, Schuligoi R, Konya V, Sturm GJ, Lippe JT, et al. Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. J Immunol. (2008) 181:7273–83. doi: 10.4049/jimmunol.181.10.7273
48. Leigh R, Vethanayagam D, Yoshida M, Watson RM, Rereich T, Inman MD, et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. (2002) 166:1212–7. doi: 10.1164/rccm.200206-509OC.

49. Gauvreau GM, Parameswaran KN, Watson RM, O’Byrne PM. Inhaled leukotriene E 4, but not leukotriene D 4, increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med. (2001) 164:1495–500. doi: 10.1164/rccm.164.8.2102033.

50. Wenzel SE, Larsen GL, Johnston K, Voelkel NF, Westcott JY. Elevated levels of leukotriene C 4 bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. (1990) 142:112–9. doi: 10.1164/ajrccm/142.1.112.

51. Manning PJ, Rakoff J, Malo JL, Ethier D, Cartier A, Girard Y, et al. Urinary leukotriene E4 levels during early and late asthmatic reactions. J Allergy Clin Immunol. (1990) 86:211–20. doi: 10.1016/S0091-6749(05)80068-5.

52. Barnes N, Thomas M, Price D, Tate H. The national montelukast survey. J Allergy Clin Immunol. (2003) 111:1157–64. doi: 10.1067/mcji.2003.103676.

53. Tager AM, Bromley SK, Medoff BD, Islam SA, Bercury SD, Friedrich EB, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are required for the development of Th2 responses and allergen-induced airway hyperresponsiveness. J Immunol. (2008) 181:1170–8. doi: 10.4049/jimmunol.181.2.1170.

54. Goodarzi K, Goodarzi M, Tager AM, Luster AD, Andrian von UH. T-cell encephalopathy in atopic mouse asthma. J Exp Med. (2010) 210:1981–10. doi: 10.1084/jem.20101563.

55. Planagumà A, Kazani S, Marigowda G, Haworth O, Mariani TJ, Israel E, et al. Leukotriene B4 receptor 1 expression on dendritic cells is required for the development of Th2 responses and allergen-induced airway hyperresponsiveness. J Immunol. (2008) 175:4217–25. doi: 10.4049/jimmunol.175.5.4217.

56. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, Israel E. Severe asthma research program, national heart, lung, and blood institute. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med. (2005) 172:824–30. doi: 10.1164/rccm.200410-1413OC.

57. Planagumà A, Kazani S, Marigowda G, Haworth O, Mariani TJ, Israel E, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med. (2008) 178:574–82. doi: 10.1164/rccm.200801-061OC.

58. Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford W, Serhan CN, et al. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J. (2007) 21:3874–8. doi: 10.1096/fj.07-8653com.

59. Dau PC, Vethanayagam D, Yoshida M, Watson RM, Rees G, et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. (2002) 166:1212–7. doi: 10.1164/rccm.200206-509OC.

60. Levy BD, De Sanctis GT, Madeira F, Toussaint W, et al. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immune responses in murine asthma. J Exp Med. (2011) 212:1073–86. doi: 10.1084/jem.20112667.

61. Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford WJ, Serhan CN, et al. CD11b depletion severely disrupts Th2 immunity in the developing lung. Immunity (2016) 45:1285–98. doi: 10.1016/j.immuni.2016.10.031.

62. Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford WJ, Serhan CN, et al. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J. (2007) 21:3874–8. doi: 10.1096/fj.07-8653com.

63. Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford WJ, Serhan CN, et al. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J. (2007) 21:3874–8. doi: 10.1096/fj.07-8653com.

64. Phythian-Adams AT, Cook PC, Lundie RJ, Jones LH, Smith KA, Barr TA, et al. CD11c depletion severely disrupts Th2 induction and development in vivo. J Exp Med. (2010) 210:2089–96. doi: 10.1084/jem.20100734.

65. Tang H, Cao W, Kasturi SP, Ravindran R, Nakaya HI, Kundu K, et al. The Th2 helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling. Nat Immunol. (2010) 11:680–17. doi: 10.1038/ni.1883.

66. Thornton EE, Looney MR, Bose O, Sen D, Sheppard D, Locksley R, et al. Phosphoinositide 3-kinase-dependent signaling abrogates the characteristic features of asthma. J Exp Med. (2005) 201:981–91. doi: 10.1084/jem.20042311.

67. Thorerton EE, Looney MR, Bose O, Sen D, Sheppard D, Locksley R, et al. Spatiotemporally separated antigen uptake by alveolar dendritic cells and airway presentation to T cells in the lung. J Exp Med. (2012) 209:1183–99. doi: 10.1084/jem.20112667.

68. Medoff BD, Seung E, Hong S, Thomas SY, Sandall BP, Duffield JS, et al. CD11b(+) myeloid cells are the key mediators of Th2 cell homing into the airway in allergic inflammation. J Immunol. (2009) 182:623–35. doi: 10.4049/jimmunol.182.1.623.

69. Guillemms M, Lambecht BN, Hammad H. Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections. Mucosal Immunol. (2013) 6:646–73. doi: 10.1038/mi.2013.14.
100. van Helden SFG, Krooshoop DJEB, Broers KCM, Raymakers RAP, Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E2determine the level of interferon-γ produced by activated human CD4 T cells. J Immunol. (2002) 168:2255–63. doi: 10.4049/jimmunol.168.5.2255

101. Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptor subtypes. J Immunol. (2006) 177:3697–703. doi: 10.4049/jimmunol.177.7.3697

102. Harizi H, Grosset C, Guilde N. Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol. (2003) 73:756–63. doi: 10.1189/jlb.1002483

103. Angel V, Farcev C, Roye O, Fontaine J, Teissier E, Capron A, et al. Role of the parasite-derived prostaglandin D2 in the inhibition of epithelial Langerhans cell migration during schistosomiasis infection. J Exp Med. (2001) 193:1135–47. doi: 10.1084/jem.193.10.1135

104. Hammad H, de Heer HJ, Soullié T, Hoogsteden HC, Trottée F, Lambrecht BN. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1, J Immunol. (2003) 171:3936–40. doi: 10.4049/jimmunol.171.8.3936

105. Robbiani DF, Finch RA, Jäger D, Muller WA, Sartorelli AC, Randolph GJ. The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell (2000) 103:757–68. doi: 10.1016/S0092-8674(00)01179-3

106. Aliaberti J, Hiensy S, Reis e Sousa C, Serhan CN, Sher A. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat Immunol. (2002) 3:76–82. doi: 10.1038/ni745

107. Hilkens C, Snejders A, Vermeulen H, Meide PVD, Wierenga E, Kapsenberg M. Accessory cell-derived interleukin-12 and prostanol J inhibit the type 1 helper T cell response and promote type 2 cytokine production in maturing human naive T helper cells. J Immunol. (1999) 153:28–35.

108. Kalinski P, Schuttemaker H, Hilkens CM, Kapsenberg ML. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol. (1998) 161:2804–9.

109. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. (2000) 164:4507–12. doi: 10.4049/jimmunol.164.9.4507

110. Lesscher PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. (2000) 164:4507–12. doi: 10.4049/jimmunol.164.9.4507

111. Hedi H, Norbert G. Inhibition of IL-6, TNF-α, and cyclooxygenase-2 expression by prostaglandin E2 in murine bone marrow-derived dendritic cells. J Immunol. (2001) 168:99–109. doi: 10.4049/jimmunol.168.5.99

112. Walker W, Rotondo D. Prostaglandin E2 is a potent inhibitor of human interleukin 12 production. J Exp Med. (1998) 181:775–9. doi: 10.1084/jem.181.2.775

113. Kalinski P, Hilkens CM, Snejders A, Snijdevint FG, Kapenberg MS. Dendritic cells, obtained from peripheral blood precursors in the presence of PGE2, promote Th2 responses. Adv Exp Med Biol. (1997) 417:363–7.

114. Kalinski P, Hilkens CM, Snejders A, Snijdevint FG, Kapenberg MS. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol. (1999) 153:28–35.

115. Kalinski P, Schuttemaker H, Hilkens CM, Kapsenberg ML. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1α+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol. (1998) 161:2804–9.

116. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. (2000) 164:4507–12. doi: 10.4049/jimmunol.164.9.4507

117. Hedi H, Norbert G. Inhibition of IL-6, TNF-α, and cyclooxygenase-2 expression by prostaglandin E2 in murine bone marrow-derived dendritic cells. J Immunol. (2001) 168:99–109. doi: 10.4049/jimmunol.168.5.99

118. Vassiliou E, Jing H, Ganea D. Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells. J Immunol. (2003) 170:320–32. doi: 10.4049/jimmunol.170.6.320

119. Harizi H, Juzan M, Pitard V, Moreau J-F, Guilde N. Cyclooxygenase-2–issued prostaglandin e2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol. (2002) 168:2255–63. doi: 10.4049/jimmunol.168.5.2255

120. Walker W, Rotondo D. Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18–induced natural killer cell interferon-gamma synthesis. Immunology (2004) 111:298–305. doi: 10.1111/j.1365-2677.2004.01810.x

121. Rieser C, Böck G, Ramoner R, Klocker H, et al. Differential deactivation of human dendritic cells by endotoxin down-regulates dendritic cell functions. J Immunol. (2004) 173:11567–74. doi: 10.4049/jimmunol.173.11.1567

122. Schuiss MJ, Willart MA, Vergote K, Gras D, Deswarte K, Ege MJ, et al. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. Science (2005) 309:1106–10. doi: 10.1126/science.aac6623

123. Scandella E, Men Y, Legler DF, Gillessen S, Priklir L, Ludewig B, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood (2004) 103:1595–61. doi: 10.1182/blood-2003-05-1643

124. van Helden SFG, Krooshoop DJEB, Broers KCM, Raymakers RAP, Figdor CG, van Leeuwen FN. A critical role for prostaglandin E2 during dendritic cell maturation. J Immunol. (2006) 177:1567–74. doi: 10.4049/jimmunol.177.7.1567

125. Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol. (2006) 176:966–73. doi: 10.4049/jimmunol.176.2.966
immune responses by prostaglandins. Arch Dermatol Res. (2000) 292:437–45. doi: 10.1007/s004030002920437.403
120. Lee YG, Jeong JY, Nyeonhui S, Berdyshev E, Chung S, Ranjan R, et al. Recruited alveolar macrophages, in response to airspace epithelial-derived monocyte chemotactrant protein 1/CCl2, regulate airway inflammation and remodeling in allergic asthma. Am J Respir Cell Mol Biol. (2015) 52:772–84. doi: 10.1165/rcmb.2014-0255OC
121. Rubio MT, Means TK, Chakraverty R, Fudaba Y, Chitenden M, et al. Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotriene receptors in human T helper lymphocytes. J Immunol. (2014) 193:5644–53. doi: 10.4049/jimmunol.0901499
122. Dwyer ER, Phipps RP. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci USA. (1996) 93:10978–83. doi: 10.1073/pnas.93.20.10978
123. Liu Q, Liu Z, Rozzo CT, Hamed HA, Alem F, Urban JF, et al. The role of B cells in the development of CD4+ T cell responses to papain following B cell receptor-independent papain uptake. J Immunol. (2014) 193:529–39. doi: 10.4049/jimmunol.1303247
124. Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D. Prostaglandin E2 regulates TH2 cytokine production.
125. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. (1991) 146:108–13.
126. Bonifácio K, Bak Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McCleanah TK, et al. Prostaglandin E2 regulates Th1 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. (2009) 206:535–48. doi: 10.1084/jem.20082292
127. Doherty TA, Khorram N, Lund S, Mehta AK, Broide DH. Lung eosinophils regulate type 2 innate lymphoid cells drive CD4+ T cell responses.
128. Liu Q, Liu Z, Rozzo CT, Hamed HA, Alem F, Urban JF, et al. The role of B cells in the development of CD4+ T cell responses to papain following B cell receptor-independent papain uptake. J Immunol. (2014) 193:529–39. doi: 10.4049/jimmunol.1303247
129. Linton P-J, Bautista B, Biederman E, Bradley ES, Harbertson J, Kondrack RM, et al. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4+ cell expansion and Th2 cytokine secretion in vivo. J Exp Med. (2003) 197:875–83. doi: 10.1084/jem.20021290
130. Rodríguez-Pinto D, Moreno J. B cells can prime naïve CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD145-CD40-dependent manner. Eur J Immunol. (2005) 35:1097–105. doi: 10.1002/eji.200425731
131. Okunishi K, Dohi M, Nakagome K, Tanaka R, Yamamoto K. A novel role for prostaglandins in regulating type 2 innate lymphoid cells expression of cysteinyl leukotriene receptor 1, which orchestrates germinal center formation and antibody class-switch via regulation of IL-17. J Immunol. (2009) 183:5644–53. doi: 10.4049/jimmunol.0901499
132. Barnig C, Cernadas M, Dutile S, Liu X, Perrella MA, Kazani S, et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med. (2013) 5:174ra26. doi: 10.1126/scitranslmed.3004812
133. Doherty TA, Khorram N, Lund S, Mehta AK, Broide DH. Lung eosinophils regulate type 2 innate lymphoid cells drive CD4+ T cell responses.
134. Yamaoka KA, Kolb J-P. Leukotriene B4 induces interleukin 5 generation from human T lymphocytes. Eur J Immunol. (1993) 23:2392–9. doi: 10.1002/eji1830231003
135. Cai Y, Kumar RK, Zhou J, Foster PS, Webb DC. Ym1/2 promotes Th2 cytokine expression by inhibiting 12/15(S)-lipoxigenase: identification of a novel pathway for regulating allergic inflammation. J Immunol. (2009) 182:5393–9. doi: 10.4049/jimmunol.0803874
136. Mirchandani AS, Besnard A-G, Yip E, Scott C, Bain CC, Cerovic V, et al. Type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates Th2 cytokine production. J Allergy Clin Immunol. (2014) 123:205–13. doi: 10.1016/j.jaci.2013.03.048
137. Fedyk ER, Phipps RP. Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J Immunol. (1992) 149:2984–91.
138. Linton P-J, Bautista B, Biederman E, Bradley ES, Harbertson J, Kondrack RM, et al. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4+ cell expansion and Th2 cytokine secretion in vivo. J Exp Med. (2003) 197:875–83. doi: 10.1084/jem.20021290
139. Rodríguez-Pinto D, Moreno J. B cells can prime naïve CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD145-CD40-dependent manner. Eur J Immunol. (2005) 35:1097–105. doi: 10.1002/eji.200425731
140. Liu Q, Liu Z, Rozzo CT, Hamed HA, Alem F, Urban JF, et al. The role of B cells in the development of CD4+ T cell responses to papain following B cell receptor-independent papain uptake. J Immunol. (2014) 193:529–39. doi: 10.4049/jimmunol.1303247
the effect of prostaglandin D2 and epithelial cytokines. J Allergy Clin Immunol. (2017) 140:1090–100.e11. doi: 10.1016/j.jaci.2016.12.958

158. Maric J, Ravindran A, Mazzurana L, Björklund ÅK, Van Acker A, Rao A, et al. Prostaglandin E2 suppresses human group 2 innate lymphoid cell function. J Allergy Clin Immunol. (2017) 141:1761–73.e6. doi: 10.1016/j.jaci.2017.09.050

159. Zhou W, Toki S, Zhang J, Goleniewksa K, Newcomb DC, Cephus JY, et al. Prostaglandin E2 signaling and inhibition of group 2 innate lymphoid cell responses. Am J Respir Crit Care Med. (2016) 193:31–42. doi: 10.1164/rccm.201410-1793OC

160. Lukic A, Larsen P, Fauland A, Samuelsson B, Wheelock CE, Gabrielson S, et al. GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures. FASEB J. (2017) 31:4370–81. doi: 10.1096/fj.201700319R

161. Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, et al. Yolk sac macrophages, fetal liver, and adult monocytes can colonize long-lived cells in the first week of life via GM-CSF. J Exp Med. (2013) 210:1977–92. doi: 10.1084/jem.20131199

162. van de Laar L, Saelens W, De Prijck S, Martens L, Scott CL, Vanhoutte L, De Prijck S, et al. Sessile alveolar macrophages communicate with alveolar epithelium to modulate immunity. Semin Immunopathol. (2016) 38:461–9. doi: 10.1007/s00281-016-0569-x

163. Upham JW, Strickland DH, Blyk N, Robinson BW, Holt PG. Alveolar macrophages from humans and rodents selectively inhibit T-cell proliferation but permit T-cell activation and cytokine secretion. Immunology (1995) 84:142–7.

164. Tang C, Ward C, Reid D, Bish R, O’Byrne PM, Walters EH. Normally suppressing CD40 coregulatory signals delivered by airway macrophages to TH2 lymphocytes are defective in patients with atopic asthma. J Allergy Clin Immunol. (2001) 107:863–70. doi: 10.1067/mai.2001.114987

165. Tang C, Inman MD, van Rooijen N, Yang P, Shen H, Matsumoto K, et al. Th type 1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFN-gamma-dependent mechanism. J Immunol. (2001) 166:1471–81. doi: 10.4049/jimmunol.166.3.1471

166. Zaslona Z, Przybranowski S, Wilke C, Van Rooijen N, Teitz-Tenilenbaum S, Osterholzer JI, et al. Resident alveolar macrophages suppress, whereas recruited monocytes promote, allergic lung inflammation in murine models of asthma. J Immunol. (2014) 193:4245–53. doi: 10.4049/jimmunol.1400580

167. Bourdonnay E, Zaslona Z, Penke LRR, Speth JM, Schneider DJ, Przybranowski S, et al. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J Exp Med. (2015) 212:729–42. doi: 10.1084/jem.20141675

168. Speth JM, Bourdonnay E, Penke LRR, Mancuso P, Moore BB, Weinberg JB, et al. Alveolar epithelial cell-derived prostaglandin E2 serves as a request signal for macrophage secretion of suppressor of cytokine signaling 3 during innate inflammation. J Immunol. (2016) 196:5112–20. doi: 10.4049/jimmunol.1502153

169. Draijer C, Booisma CE, Reker-Smit C, Post E, Poelstra K, Melgert BN. PGE2-treated macrophages inhibit development of allergic lung inflammation in mice. J Leukoc Biol. (2016) 100:95–102. doi: 10.1189/jlb.3MAB1115-505R

170. Ohta S, Imamura M, Xing W, Boyce JA, Balestrieri B. Group V secretory phospholipase A2 is involved in macrophage activation and is sufficient for macrophage effector functions in allergic pulmonary inflammation. J Immunol. (2013) 190:5927–38. doi: 10.4049/jimmunol.1203202

171. Yamaguchi M, Zacharia J, Laidlaw TM, Balestrieri B, PLA2G5 regulates transglutaminase activity of human IL-4-activated M2 macrophages through PGE2 generation. J Leukoc Biol. (2016) 100:131–41. doi: 10.1189/jlb.3A0815-372R

172. Lauzon-Josef J-F, Marsolais D, Langlois A, Bissossonette EY. Dysregulation of alveolar macrophages unleashes dendritic cell-mediated mechanisms of allergic airway inflammation. Mucosal Immunol. (2014) 7:155–64. doi: 10.1038/mi.2013.34

173. Samuchival SK, Balestrieri B, Raif H, Boyce JA. Endogenous prostaglandin E2 amplifies IL-33 production by macrophages through an E prostaglandin (EP) 2/EP 4-cAMP-EPAC-dependent pathway. J Biol Chem. (2017) 292:8195–206. doi: 10.1074/jbc.M116.769422

174. Jandl K, Stacher E, Balint Z, Sturm EM, Maric J, Peinhaupt M, et al. Activated prostaglandin D2 receptors on macrophages enhance neutrophil recruitment into the lung. J Allergy Clin Immunol. (2016) 137:833–43. doi: 10.1016/j.jaci.2015.11.012

175. Shirey KA, Lai W, Pletneva LM, Puche AC, Keegan AD, Prince GA, Blanco JC G, et al. Activated alveolar macrophages recruit lungs to a pro-inflammatory state in adult mice. J Exp Med. (2014) 213:291–300. doi: 10.1084/jem.2013.6.10

176. Shirey KA, Lai W, Pletneva LM, Karp CL, Divanovic S, Blanco JC G, et al. Role of the lipoxigenase pathway in RSV-induced alternative activated macrophages leading to resolution of lung pathology. Mucosal Immunol. (2013) 7:549–57. doi: 10.1038/mi.2013.71

177. Clarke DL, Davis NHE, Campion CL, Foster ML, Heasman SC, Lewis AR, et al. Dectin-2 sensing of house dust mite is critical for the initiation of allergic airway inflammation. J Immunol. (2008) 180:541–9. doi: 10.4049/jimmunol.180.1.541

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.